Loading...
A large, multicenter, randomized trial presented at the 2007 American Academy of Neurology meeting failed to demonstrate efficacy of recombinant factor VIIa (rFVIIa) for nontraumatic intracranial hemorrhage (not yet published). However, scant attention has been paid to this agent’s potential therapeutic role in traumatic brain injury, particularly in patients with coagulopathy from either anticoagulants or the traumatic intracranial hemorrhage itself. In a prospective observational analysis, researchers at a single level I trauma center report their experience with rFVIIa treatment during 1 year in 15 patients (mean age, 61) with traumatic intracranial hemorrhage and coagulopathy (international normalized ratio >1.3) who needed immediate su…